ADRX ADARx Pharmaceuticals, Inc.
Fundamentals / CIK 0001802369 / USDADARx Pharmaceuticals, Inc. reported $929.1M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open ADRX in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$901.0M Total debt: $6.46M
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Revenue | $2.22M | -- | -- | $1.55M | -- | -- |
| Research & Development | $26.71M | -- | -- | $19.42M | -- | -- |
| Selling, General & Admin | $7.68M | -- | -- | $5.15M | -- | -- |
| Total Operating Expenses | $34.39M | -- | -- | $24.56M | -- | -- |
| Operating Income | -$32.18M | -- | -- | -$23.01M | -- | -- |
| EBITDA | -$31.88M | -- | -- | -$22.71M | -- | -- |
| Interest Income | $3.48M | -- | -- | $4.62M | -- | -- |
| Net Income | -$28.12M | -$25.76M | -$22.67M | -$17.88M | -$18.09M | -$15.55M |
| Basic EPS | -$1.74 | -- | -- | -$1.85 | -- | -- |
| Diluted EPS | -$1.74 | -- | -- | -$1.85 | -- | -- |
| Basic Shares Outstanding | 16.1M | -- | -- | 9.7M | -- | -- |
| Diluted Shares Outstanding | 16.1M | -- | -- | 9.7M | -- | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2025-12-31 |
|---|---|---|
| Cash & Cash Equivalents | $570.6M | $66.52M |
| Short-Term Investments | $330.4M | $413.5M |
| Cash & Short-Term Investments | $901.0M | $480.0M |
| Total Current Assets | $918.5M | $493.4M |
| Property, Plant & Equipment, Net | $4.40M | $4.73M |
| Other Non-Current Assets | $100K | $2.21M |
| Total Non-Current Assets | $10.55M | $14.28M |
| Total Assets | $929.1M | $507.7M |
| Accounts Payable | $9.35M | $5.84M |
| Deferred Revenue (Current) | $20.92M | $16.56M |
| Total Current Liabilities | $43.57M | $30.48M |
| Total Non-Current Liabilities | $311.1M | $321.8M |
| Total Liabilities | $354.7M | $352.3M |
| Total Debt (incl. Leases) | $6.46M | $7.74M |
| Common Stock | $11K | $0 |
| Retained Earnings | -$297.2M | -$220.7M |
| Accumulated Other Comp. Income | -$2.15M | $1.96M |
| Total Stockholders' Equity | $574.4M | -$202.3M |
| Total Equity | $574.4M | -$202.3M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$28.12M | -$25.76M | -$22.67M | -$17.88M | -$18.09M | -$15.55M |
| Depreciation & Amortization | $300K | -- | -- | $300K | -- | -- |
| Stock-Based Compensation | $1.9K | -- | -- | $1.4K | -- | -- |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 21.08x | -- | -- | -- | -- | -- |
| Quick Ratio | 20.68x | -- | -- | -- | -- | -- |
| Debt to Equity | 0.01x | -- | -- | -- | -- | -- |
| Revenue Growth (YoY) | +42.6% | -- | -- | -- | -- | -- |